Last reviewed · How we verify
12 months of P2Y12 receptor antagonist — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
12 months of P2Y12 receptor antagonist (12 months of P2Y12 receptor antagonist) — Beijing Anzhen Hospital.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| 12 months of P2Y12 receptor antagonist TARGET | 12 months of P2Y12 receptor antagonist | Beijing Anzhen Hospital | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- 12 months of P2Y12 receptor antagonist CI watch — RSS
- 12 months of P2Y12 receptor antagonist CI watch — Atom
- 12 months of P2Y12 receptor antagonist CI watch — JSON
- 12 months of P2Y12 receptor antagonist alone — RSS
Cite this brief
Drug Landscape (2026). 12 months of P2Y12 receptor antagonist — Competitive Intelligence Brief. https://druglandscape.com/ci/12-months-of-p2y12-receptor-antagonist. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab